PMID- 37268640
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230609
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Jun 2
TI  - Determinants of arterial stiffness in patients with type 2 diabetes mellitus: a 
      cross sectional analysis.
PG  - 8944
LID - 10.1038/s41598-023-35589-4 [doi]
LID - 8944
AB  - In patients with type 2 diabetes mellitus (T2DM) arterial stiffness is associated 
      with increased cardiovascular and total mortality. Little is known about 
      determinants of arterial stiffness in clinical routine. Identification of 
      potential determinants of arterial stiffness will help to address treatment 
      targets for patients in the early state of T2DM. This is a cross-sectional 
      analysis of arterial stiffness in 266 patients in the early stage of T2DM who did 
      not have cardiovascular or renal complications. Parameters of arterial stiffness 
      such as central systolic blood pressure (cSBP), central pulse pressure (cPP) and 
      pulse wave velocity (PWV) were measured with the SphygmoCor System (AtCor 
      Medical). We investigated the influence of parameters of glucose metabolism, 
      lipid status, body constitution, blood pressure (BP) and inflammation on the 
      stiffness parameters using multivariate regression analysis. The study cohort 
      consisted of male and female patients aged 61 +/- 8 years with mean diabetes 
      duration of 6.4 +/- 5.1 years, mean HbA1c 7.1 +/- 0.9%, mean cSBP 121 +/- 12 mmHg, mean 
      cPP 44 +/- 10 mmHg and mean PWV 8.9 +/- 1.8 m/s. Multiple regression analysis 
      identified waist circumference (WC) (beta = 0.411, p = 0.026), LDL-cholesterol 
      (beta = 0.106, p = 0.006), systolic office BP (beta = 0.936, p < 0.001) and 
      diabetes duration (beta = 0.233, p = 0.043) as potential determinants of cSBP. 
      cPP was determined by sex (beta = 0.330, p = 0.008), age (beta = 0.383, 
      p < 0.001), systolic office BP (beta = 0.370, p < 0.001) and diabetes duration 
      (beta = 0.231, p = 0.028) whereas for PWV the following determinants could be 
      identified: age (beta = 0.405, p < 0.001), systolic office BP (beta = 0.421, 
      p < 0.001) and diabetes duration (beta = 0.073, p = 0.038). In addition to the 
      known parameters age, sex and systolic office BP serum LDL-cholesterol, WC and 
      diabetes duration have been identified as determinants of arterial stiffness in 
      patients with T2DM. Treatment of patients in the early stage of T2DM should focus 
      on these clinical parameters to prevent progression of arterial stiffness and as 
      a consequence reduce cardiovascular mortality.Trial registration: The patients 
      included in the analysis participated in one of the following clinical trials 
      NCT02752113 (registered 26.4.2016), NCT02383238 (09.03.2015), NCT02471963 
      (15.06.2015), NCT01319357 (21.03.2011) ( http://www.clinicaltrials.gov ).
CI  - (c) 2023. The Author(s).
FAU - Staef, Mawadah
AU  - Staef M
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
FAU - Ott, Christian
AU  - Ott C
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
AD  - Paracelsus Medical School Nuremberg, Nuremberg, Germany.
FAU - Kannenkeril, Dennis
AU  - Kannenkeril D
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
FAU - Striepe, Kristina
AU  - Striepe K
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
FAU - Schiffer, Mario
AU  - Schiffer M
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
FAU - Schmieder, Roland E
AU  - Schmieder RE
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
FAU - Bosch, Agnes
AU  - Bosch A
AD  - Department of Nephrology and Hypertension, Friedrich-Alexander-University 
      Erlangen-Nurnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany. 
      agnes.bosch@uk-erlangen.de.
LA  - eng
SI  - ClinicalTrials.gov/NCT02471963
SI  - ClinicalTrials.gov/NCT01319357
SI  - ClinicalTrials.gov/NCT02752113
SI  - ClinicalTrials.gov/NCT02383238
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230602
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Humans
MH  - Male
MH  - Female
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Cross-Sectional Studies
MH  - *Vascular Stiffness
MH  - Pulse Wave Analysis
MH  - Blood Pressure
MH  - Cholesterol/therapeutic use
PMC - PMC10238522
COIS- The authors declare no competing interests.
EDAT- 2023/06/03 11:42
MHDA- 2023/06/05 06:43
PMCR- 2023/06/02
CRDT- 2023/06/02 23:16
PHST- 2022/11/29 00:00 [received]
PHST- 2023/05/20 00:00 [accepted]
PHST- 2023/06/05 06:43 [medline]
PHST- 2023/06/03 11:42 [pubmed]
PHST- 2023/06/02 23:16 [entrez]
PHST- 2023/06/02 00:00 [pmc-release]
AID - 10.1038/s41598-023-35589-4 [pii]
AID - 35589 [pii]
AID - 10.1038/s41598-023-35589-4 [doi]
PST - epublish
SO  - Sci Rep. 2023 Jun 2;13(1):8944. doi: 10.1038/s41598-023-35589-4.